China's Xinhua news agency reported that scientist Jiankui He allegedly used falsified ethical review papers to persuade couples to participate in his CRISPR/Cas9 experiments.
There really is enough CRISPR to go around. On Tuesday Allergan and Editas struck a deal to apply the gene-editing approaching in certain ocular conditions, including Leber congenital amaurosis.
Join us on February 26 at 3 pm ET, and we’ll dive into the key areas where practices are losing time and money and provide solutions to overcome them.
Scientific advisors to the President are calling for an urgent update to the national biodefense strategy as CRISPR, gene editing, and other biotechnology fields advance at a rapid pace.
Beyond being a revolutionary research tool, CRISPR/Cas9 also holds enormous potential for changing medicine, and this has certainly attracted the attention of the business and investor community in biotech.
The hot gene editing company plans to raise a comparatively small amount of money in its IPO, when considering the amount of money it's raised privately.
CRISPR gene editing is heralded one of the most promising technologies today - and it's ramping up fast. Here's a commercial timeline - from just the past year.
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
Also, docs admit bias against patients, KaloBios stock crashes and mobile health app users fear hacks.
Looks like the gene editing startup plans to start with simple gene editing techniques that focus heavily on diseases of the eye.
The companies will develop new therapeutics targeted at blood disorders, blindness and congenital heart disease.
Transposagen, a Kentucky biotech that develops research tools and animal models for drug discovery, will add CRISPR technology to its existing suite of gene editing tools.
Zelis CEO Amanda Eisel shares her perspective on how the company is solving the problems of a fragmented health financial system to benefit all.
Isis Pharmaceuticals has teamed up with UCSD to demonstrate a commercially feasible way to use RNA to control CRISPR gene editing.
Looks like CRISPR is headed to the clinic: Editas Medicine just announced that it'll bring this gene editing technology to human trials by 2017.
Vertex Pharmaceuticals, known for its line of cystic fibrosis drugs, has entered the gene editing space with a new $105 million deal with CRISPR Therapeutics.
The market potential of CRISPR technology has been legitimized by Editas Medicine's impressive, $120 million fundraise. Here are six more biotechs shaping the CRISPR landscape look like now? And what other players are in this game?
CRISPR gene editing technology is one of the most intriguing growth fields in biotech, says Deerfield Management president Jim Flynn. The venture firm just launched a new $550 million fund, and it'll focus on seeding startups and funding new companies - and is very interested in this space.